



May 6, 2022

Dear Valued Customer,

As you may know, one of the major US suppliers of iodinated contrast media in the United States is currently experiencing a supply shortage due to the stringent COVID restrictions in Shanghai. On May 6<sup>th</sup>, the American College of Radiology (ACR) posted a statement addressing this worldwide shortage; please review the [message at this link](#) for ACR's guidance on how to manage your practice.

**These restrictions are not impacting Bracco products supplying the North American market.** Given the shortage of this major supplier, over the past week Bracco has experienced an influx of orders from facilities looking to purchase Isovue® (iopamidol injection).

Bracco has taken several measures to protect our Isovue inventory and to ensure we have enough product for our committed customers like you. These measures include investing in increased Isovue manufacturing capacity, a focus on manufacturing our high-volume SKUs and implementation of a direct purchase model to allow for more control of inventory. **At this time, we do not anticipate any Isovue issues in the foreseeable future and will continue to monitor this situation.**

**Today, in order to ensure that we maintain a steady supply for you and your patients, we have implemented a new process for our existing committed customers.**

#### What does that mean?

- Effective last week, we started an order review process to ensure our committed customers are receiving product.
- Starting today, BDI systems are in place to process orders based on your facilities' average order quantity. These orders will be processed immediately, and will be shipped within your contracted shipping timeframe.
- Any orders over that quantity will be placed on hold and manually reviewed. If large stocking orders are placed, there will be a delay of approximately one week for processing, and the order will be fulfilled at your average order quantity; the remaining order quantity will be cancelled.

#### How can you help?

- Place orders in the normal process and quantity for your facility.
- Do not place large stocking orders as they will strain the system and cause delays for you and other facilities

1

#### **Bracco Diagnostics Inc.**

259 Prospect Plains Road, Bldg. H – Monroe Township, NJ 08831 USA  
Telephone: (609) 514-2200 / (800) 631-5245 / Fax: 609-514-2424 / [imaging.bracco.com/us-en](http://imaging.bracco.com/us-en)

**Bracco Group**

Thank you for your help as we manage through the next few months. As always, we are dedicated to ensuring a steady supply for you, our committed customer. Using this new process, and with your help, we do not anticipate any Isovue stockouts in the foreseeable future.

Thank you for your continued partnership.

### **ISOVUE® (Iopamidol Injection)**

#### **Indications and Usage:**

#### **ISOVUE® -200, 250, 300, 370**

ISOVUE® (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiology, or for adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.

#### **ISOVUE® -300 (Iopamidol Injection 61%) and ISOVUE® -370 (Iopamidol Injection 76%) Imaging Bulk Package\***

ISOVUE® (Iopamidol Injection) Imaging Bulk Package (IBP) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiology; or for intravenous contrast enhancement of computed tomographic (CECT) imaging of the head and body in adult and pediatric patients.

\*The ISOVUE (Iopamidol Injection) Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

#### **IMPORTANT SAFETY INFORMATION:**

ISOVUE (Iopamidol Injection) IS NOT FOR INTRATHECAL USE. Iopamidol Injection is available as ISOVUE-M 200 (Iopamidol Injection 41%), and ISOVUE-M 300 (Iopamidol Injection 61%) for intrathecal administration.

Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events.

As with all injectable contrast agents, the possibility of severe reactions should be borne in mind, regardless of the patient's pre-existing medical history. As with any other iodinated contrast media, caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are

administered. Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration.

**Please see full Prescribing Information for ISOVUE (Iopamidol Injection) at <https://imaging.bracco.com/us-en/products/ct-ct-colonography/isovue>**

**Please see full Prescribing Information for ISOVUE Imaging Bulk Package products at <https://imaging.bracco.com/us-en/products/ct-ct-colonography/isovue>**


**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.**

ISOVUE is currently manufactured for Bracco Diagnostics Inc. at three locations: BIPSO GmbH, Singen (Germany), Patheon Italia S.p.A., Ferentino (Italy) and S. M. Farmaceutici SRL, Tito (Italy).

ISOVUE and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc.

© 2022 Bracco Diagnostics Inc. All Rights Reserved.

Best Regards,

A handwritten signature in black ink, appearing to read "Travis Smith", written on a light-colored background.

Travis Smith  
Executive Director, US Sales  
Bracco Diagnostics, Inc.